Grant of Interim Extension of the Term of U.S. Patent No. 5,454,779; ResQPump®/ResQPOD® ITD, 61579 [2012-24856]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 196 / Wednesday, October 10, 2012 / Notices
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No. PTO–P–2012–0039]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,454,779;
ResQPump®/ResQPOD® ITD
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a one-year interim
extension of the term of U.S. Patent No.
5,454,779.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to Mary.
Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On September 6, 2012, the Regents of
the University of California timely filed
an application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
U.S. Patent No. 5,454,779. The patent
claims the medical device, ResQPump®
in connection with the ResQPOD® ITD.
The application indicates that a
Premarket Approval Application, PMA
No. P110024, for the medical device has
been filed, and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the original
expiration date of the patent, October 3,
rmajette on DSK2TPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:15 Oct 09, 2012
Jkt 229001
2012, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,454,779 is granted for a period of one
year from the original expiration date of
the patent.
Dated: September 27, 2012.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2012–24856 Filed 10–9–12; 8:45 am]
BILLING CODE 3510–16–P
BUREAU OF CONSUMER FINANCIAL
PROTECTION
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Bureau of Consumer Financial
Protection.
ACTION: Notice and request for comment.
AGENCY:
The Bureau of Consumer
Financial Protection (Bureau), as part of
its continuing effort to reduce
paperwork and respondent burden,
invites the general public and other
Federal agencies to take this
opportunity to comment on proposed
information collections, as required by
the Paperwork Reduction Act of 1995.
The Bureau is soliciting comments
concerning its proposed information
collections titled, ‘‘Generic Clearance
for Collection of Information on
Compliance Costs and Other Effects of
Regulations.’’ A proposed collection has
been submitted to the Office of
Management and Budget (OMB) for
review and approval. A copy of the
submission, including copies of a
proposed collection and supporting
documentation, may be obtained by
contacting the agency contact listed
below.
SUMMARY:
Written comments are
encouraged and must be received on or
before November 9, 2012 to be assured
of consideration.
ADDRESSES: You may submit comments,
identified by agency name and Generic
Clearance for Collection of Information
on Compliance Costs and Other Effects
of Regulations, to:
• Agency: Consumer Financial
Protection Bureau (Attention: PRA
Office), 1700 G Street NW., Washington,
DC 20552; (202) 435–9011; and CFPB_
Public_PRA@cfpb.gov.
• OMB: Shagufta Ahmed, Office of
Management and Budget, New
DATES:
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
61579
Executive Office Building, Room 10235,
Washington, DC 20503; (202) 395–7873.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
should be directed to Consumer
Financial Protection Bureau (Attention:
PRA Office), 1700 G Street NW.,
Washington, DC 20552, (202) 435–9011,
or through the internet at CFPB_Public_
PRA@cfpb.gov.
SUPPLEMENTARY INFORMATION:
Title: Generic Clearance for Collection
of Information on Compliance Costs and
Other Effects of Regulations.
OMB Control Number: 3170–XXXX.
Type of Review: New generic
collection.
Abstract: Congress created the Bureau
in July 2010 through the Dodd-Frank
Wall Street Reform and Consumer
Protection Act, Public Law 111–203,
Title X (the Dodd-Frank Act), and the
Bureau assumed certain rulemaking
authorities in July 2011. The DoddFrank Act accords the Bureau
responsibility for implementing,
interpreting, and assuring compliance
with various Federal consumer financial
protection products and services. As
outlined in the Dodd-Frank Act, among
the Bureau’s objectives is to identify
regulations that are ‘‘outdated,
unnecessary, or unduly burdensome’’ in
order to reduce unwarranted regulatory
burdens. In order to help support this
objective, the Bureau must fully
understand the implications of its
regulations. Therefore, the Bureau seeks
to collect qualitative information on
compliance costs and other impacts of
existing consumer financial regulations
and any new potential rules the Bureau
may propose.
The collections seek qualitative
information on the impact of regulations
on providers of consumer financial
products and services (Providers). The
Bureau seeks to better understand the
compliance activities, burdens, and
other economic costs and benefits
associated with its potential rules and
existing regulations. Additional input
from Providers would give the Bureau a
more nuanced understanding of costs,
which it can use to provide solutions for
reducing undue regulatory burden on
Providers. To that end, the Bureau
anticipates seeking to use the
information from these collections to:
• Inform the Bureau’s various
rulemaking initiatives announced in the
Bureau’s regulatory agenda, most of
which concern the mortgage industry; 1
1 Consumer Financial Protection Bureau, ‘‘Fall
2011 Statement of Regulatory Priorities,’’ (available
at https://www.consumerfinance.gov/regulations/
fall-2011-statement-of-regulatory-priorities/);
E:\FR\FM\10OCN1.SGM
Continued
10OCN1
]]>Agencies
[Federal Register Volume 77, Number 196 (Wednesday, October 10, 2012)]
[Notices]
[Page 61579]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24856]
[[Page 61579]]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No. PTO-P-2012-0039]
Grant of Interim Extension of the Term of U.S. Patent No.
5,454,779; ResQPump[supreg]/ResQPOD[supreg] ITD
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,454,779.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On September 6, 2012, the Regents of the University of California
timely filed an application under 35 U.S.C. 156(d)(5) for an interim
extension of the term of U.S. Patent No. 5,454,779. The patent claims
the medical device, ResQPump[supreg] in connection with the
ResQPOD[supreg] ITD. The application indicates that a Premarket
Approval Application, PMA No. P110024, for the medical device has been
filed, and is currently undergoing regulatory review before the Food
and Drug Administration for permission to market or use the product
commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review
period will continue beyond the original expiration date of the patent,
October 3, 2012, interim extension of the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,454,779 is granted for a period of one year from the
original expiration date of the patent.
Dated: September 27, 2012.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2012-24856 Filed 10-9-12; 8:45 am]
BILLING CODE 3510-16-P
